Clinical Evaluation of Chronic Hepatitis C and Indications for HCV Treatment

The drug treatment of hepatitis C represents a great therapeutic advance in favor of the elimination of the virus. The present study assessed the efficacy of treatment regimens involving direct action antivirals (DAAs), given to patients with chronic hepatitis C, attended at a referral hospital of infectology, central Brazil. This is a descriptive and cross - sectional study, based on the electronic database of the outpatient pharmacy, that evaluated the characteristics of patients and drug regimens involving DAA, from November 2015 to June 2017. Among 717 patients enrolled in this study, most of them had advanced liver fibrosis, were treatment naïve and HCV genotype 1 infected almost 80% of participants. A high efficacy of HCV treatment was achieved with 97% (95% CI: 94.9-98.2%) of SVR among the 431 patients who presented the results of viral load tests (HCV-RNA) at 12 weeks post-treatment. Patients infected with genotype 3 and who were cirrhotic had a lower SVR rate (87%). Treatment efficacy was not associated with age or sex among participants. The results of this study corroborate the findings in literature that showed a high efficacy of DAAs in the treatment of chronic hepatitis C, implemented through the clinical protocol and therapeutic guidelines for hepatitis C of the Ministry of Health in 2015. Many challenges must be overcome in order to combating viral hepatitis. In this context, the efficacy of HCV treatment it is an important issue to achieve the HCV elimination as a public health threat

Download Full-text

A novel model to improve access to care for patients with chronic hepatitis C attended in behavioral health facilities

Gastroenterology & Hepatology Open Access ◽

10.15406/ghoa.2021.12.00459 ◽

2021 ◽

Vol 12 (2) ◽

pp. 74-77

Author(s):

Ahmed Shady ◽

Marybeth Santiago ◽

Holly Totouom Tangho ◽

Ronnie Swift ◽

Nora V Bergasa

Keyword(s):

Quality Of Life ◽

New York ◽

Chronic Hepatitis ◽

Hepatitis C ◽

Replacement Therapy ◽

Behavioral Health ◽

Chronic Hepatitis C ◽

Hcv Treatment ◽

Opioid Replacement Therapy

Background: Chronic hepatitis C (C-HCV) is more prevalent in individuals with behavioral health (BH) diagnoses and those on opioid replacement therapy than in other groups. Accordingly, our aim was to evaluate the effect of C-HCV treatment on the quality of life (QOL) of individuals receiving opioid replacement therapy in a newly created C-HCV clinic attached to the methadone clinic in our 338 beds and 355,702 annual outpatient visits community hospital, serving the population of East Harlem, New York City, where it is located. Methods: Adult patients with behavioral health diagnoses were screened for C-HCV upon entry to the hospital and were referred for evaluation and treatment, as appropriate. The effect of treatment of C-HCV on the quality of life (QOL) was assessed by a questionnaire in which a maximum score of 174 is the worst QOL, and a score of zero is the best, at baseline, and at least 12 weeks post treatment. Results: Three hundred and eighty-seven patients with behavioral health diagnoses were screened. One hundred and fifteen of them had confirmed C-HCV. Twenty-one of those patients had attended the BH HCV clinic. Fourteen additional patients were evaluated at a later date. Nineteen patients agreed to participate in the QOL study. Of these, 15 (79%) completed therapy and were cured. A marked improvement in their QOL scores was documented at least 12 weeks after treatment. Conclusion: A model of care that includes C-HCV treatment in BH facilities leads to adherence to therapy and cure, which is associated with improved QOL and should be the standard practice.

Download Full-text

PGI2 CHRONIC HEPATITIS C VIRUS (HCV) TREATMENT COSTS IN THE TERTIARY REFERENCE HOSPITAL DAS CLÍNICAS—UNIVERSITY OF SÃO PAULO SCHOOL OF MEDICINE (HC-FMUSP)

Value in Health ◽

10.1016/s1098-3015(10)75406-1 ◽

2009 ◽

Vol 12 (7) ◽

pp. A508

Author(s):

MA Nabeshima ◽

R Ferreira ◽

SL Cipriano ◽

FJ Carrilho ◽

SK Ono-Nita

Keyword(s):

Chronic Hepatitis ◽

Hepatitis C Virus ◽

Hepatitis C ◽

Chronic Hepatitis C ◽

Sao Paulo ◽

Treatment Costs ◽

Hcv Treatment ◽

School Of Medicine ◽

Chronic Hepatitis C Virus ◽

Reference Hospital

Download Full-text

Response of Ns5a inhibitors resistant patients to Qurevo-Sovaldi-Ribavirin regimen as a retreatment strategy for chronic hepatitis c virus infection

QJM ◽

10.1093/qjmed/hcab100.139 ◽

2021 ◽

Vol 114 (Supplement_1) ◽

Author(s):

Ahmed A Moanes ◽

Hesham H Radwan ◽

Yasser O Abd El Rahman ◽

Mostafa M Abd El Nabi

Keyword(s):

Chronic Hepatitis ◽

Hepatitis C Virus ◽

Hepatitis C ◽

Sustained Virological Response ◽

Chronic Hepatitis C ◽

Virological Response ◽

Hcv Treatment ◽

Number Of Patients ◽

Chronic Hepatitis C Virus ◽

Chronic Hcv

Abstract Background Hepatitis C Virus (HCV) infection is a major global health challenge; it is estimated that more than 80 million people are chronically infected worldwide, with 3–4 million new infections and 350 000 deaths occurring each year because of HCV-related complications. Aim of the work to determine the efficacy of Qurevo-Sovaldi-Ribavirin regimen as a retreatment strategy in NS5A inhibitors (Sofosbuvir & Daclatasvir) resistant patients infected with chronic hepatitis C virus. Patients and Methods An observational cross-sectional study was carried out on 20 chronic hepatitis C virus infected patients in The centre of HCV treatment at El Quabary specialized centers in Alexandria where large number of patients receiving their HCV treatment. Results all patients (20/20) achieved sustained virological response after 3 months of the last dose of treatment (SVR12). Conclusion the new retreatment strategy composed of the triple therapy Qurevo (Ombitasvir/Paritaprevir/Ritonavir)/Sofosbuvir/Ribavirin is effective in the treatment of chronic HCV infected patients previously treated with Sofosbuvir/Daclatasvir/Ribavirin for 12 weeks without achieving sustained virological response (Ns5a inhibitors resistant chronic HCV patients).

Download Full-text

Thailand practice guideline for management of chronic hepatitis C 2018

Thai Journal of Hepatology ◽

10.30856/th.jhep2018vol1iss3_12 ◽

2018 ◽

Vol 1 (3) ◽

pp. 50-60

Author(s):

THASL Committee

Keyword(s):

Chronic Hepatitis ◽

Hepatitis C ◽

Chronic Hepatitis C ◽

Practice Guideline ◽

Treatment Strategies ◽

Antiviral Agent ◽

Hcv Treatment ◽

Direct Acting Antiviral ◽

The North ◽

Direct Acting

Chronic hepatitis C is one of the important cause of chronic liver diseases leading to cirrhosis and hepatocellular carcinoma worldwide. The prevalence of chronic hepatitis C in Thailand is about 1 - 5% where the prevalence is higher in the north and northeastern. Treatment of chronic hepatitis C has been developed and markedly improved in the last 3 decades. Since the advanced development of direct acting antiviral agent (DAA), treatment of chronic hepatitis C has been much improved not only in the efficacy but also tolerability and safety. IFN-free DAA treatment become a standard therapy in many country including Thailand. Due to fast development of HCV treatment strategies, Thailand Association for the Study of the Liver Disease has recurrently developed practice guideline for management of chronic hepatitis C in order to practically guide and to significantly improve HCV treatment in Thailand. The article reveals the detail of Thailand practice guideline for management of chronic hepatitis C 2018

Download Full-text

Successful treatment of chronic hepatitis C virus infection in a patient receiving daily peritoneal dialysis

American Journal of Health-System Pharmacy ◽

10.2146/ajhp160729 ◽

2017 ◽

Vol 74 (19) ◽

pp. 1541-1544 ◽

Cited By ~ 5

Author(s):

Jennifer E. Stark ◽

Jennifer Cole

Keyword(s):

Chronic Hepatitis ◽

Peritoneal Dialysis ◽

Hepatitis C ◽

Chronic Hepatitis C ◽

Fixed Dose ◽

Hcv Treatment ◽

Once Daily ◽

Genotype 1A ◽

Chronic Hepatitis C Virus ◽

Dose Combination

Abstract Purpose Successful use of a 4-drug oral fixed-dose combination therapy to treat chronic hepatitis C in a patient receiving peritoneal dialysis (PD) is reported. Summary New highly effective treatments for chronic hepatitis C virus (HCV) infection are now available, but safety and efficacy data on the use of anti-HCV therapies in patients with renal failure, particularly those requiring PD, remain limited. A 73-year-old black man with chronic HCV genotype 1a infection and stage 5 chronic renal disease requiring daily automated PD was referred for HCV treatment prior to renal transplantation. HCV treatment was initiated with paritaprevir–ritonavir–ombitasvir– dasabuvir, or “PrOD” (a combination tablet containing paritaprevir 75 mg, ritonavir 50 mg, and ombitasvir 12.5 mg to be taken once daily and a dasabuvir sodium 250-mg tablet to be taken twice daily), in conjunction with ribavirin 200 mg once daily. After a 12-week course of PrOD therapy, during which ribavirin therapy was tapered and then discontinued at week 10 and subcutaneous epoetin alfa was administered for anemia control from weeks 4 to 12, the patient’s HCV viral load was undetectable; a sustained virologic response at 12 weeks (SVR12) was noted. Conclusion A patient with end-stage renal disease requiring PD was treated successfully for HCV genotype 1a infection with PrOD fixed-dose combination therapy plus ribavirin therapy. The patient achieved an SVR12 despite withdrawal of ribavirin at treatment week 10, with minimal adverse effects reported.

Download Full-text